Cutaneous Radiation Injury
Skin’s reaction to insult from radiation, commonly referred to as Cutaneous Radiation Injury (CRI), resulting from exposure to ionizing radiation is currently an un-solved issue. CRI patients experience moist desquamation, ulceration, and/or necrosis. Severe cases of CRI can become fatal. Unfortunately, radiation exposure is a real threat in today’s world and a threat to national security. No current standards of care exist for CRI treatment.
Pre-Clinical Studies Show:
- Compared to controls, KeraStat improved metrics of ulceration, epidermal atrophy, dermal inflammation.
- Treatment with KeraStat found to accelerate healing and reduced the appearance of moist desquamation in CRI.
Radiation Dermatitis (RD)
Approximately 85% of cancer patients who undergo radiation therapy treatment experience at least some degree of radiation dermatitis (RD). No effective standard of care treatment exists. RD can profoundly impact patient quality of life. Effects can be mild to severe; 25% of patients experience moist desquamation, ulceration, and necrosis. RD can interrupt radiation therapy (RT) resulting in inadequate or delayed treatment. There is a significant unmet need for products that decrease severity and injury time.
Clinical Studies Show:
- KeraStat Cream reduces the severity of RD compared to standard of care.